Cytokinetics, Incorporated CYTK
64.66
(1.00)
(1.52%)
as of 25 Sep
- Market cap
- $9.0B
- P/E
- 0.0×
Follow CYTK
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 329.76% | 151.81% | 197.47% | 281.08% |
+8 more TTM periods Free account |
|
| (56.76%) | (65.39%) | (55.55%) | (52.35%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(80.83%) | (114.79%) | (98.90%) | (82.52%) | |
Average Days of Receivables |
131.78 | 23.55 | 73.65 | 7.57 | |
Free Cash Flow per Share |
(4.40) | (4.45) | (4.45) | (3.78) | |
Free Cash Flow |
(580.71) | (548.92) | (534.82) | (453.38) | |
Capital Expenditures |
(25.26) | (25.07) | (24.81) | (20.45) | |
Piotroski F-Score |
1.00 | 2.00 | 2.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(25.96%) | (45.37%) | (36.96%) | (28.34%) | |
Accounts Receivable Turnover |
4.12 | 23.94 | 5.12 | 85.00 | |
Accounts Payable Turnover |
0.66 | 0.43 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | — | — | |
Average Days of Payables |
616.70 | 1,073.54 | 0.00 | 0.00 | |
Days of Inventory on Hand |
11.43 | 6.69 | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
592.52% | 390.58% | 472.55% | 460.10% | |
Selling, General and Administrative Expense of Revenue |
547.47% | 313.56% | 322.89% | 292.26% | |
Share Based Compensation of Revenue |
188.13% | 112.58% | 127.54% | 123.87% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.62 | 0.63 | 0.65 | 0.58 | |
Depreciation/Fixed assets |
0.16 | 0.14 | 0.13 | 0.13 | |
Capex/Depreciation |
(2.01) | (2.24) | (2.45) | (2.12) | |
Revenue per Share |
0.51 | 0.86 | 0.73 | 0.73 | |
Operating CF per Share |
(4.21) | (4.25) | (4.25) | (3.61) | |
Capex per Share |
(0.19) | (0.20) | (0.21) | (0.17) | |
Capex to Sales |
0.37 | 0.24 | 0.28 | 0.23 | |
Net Profit Margin |
(1,321.12%) | (784.02%) | (891.60%) | (862.21%) |
Columns are period end dates